

ESEARCH OPPORTUNITY ALERTS

Issue 40: Volume 1b



GRANTS FROM NATIONAL INSTITUTES OF HEALTH (NIH)

(August – October, 2021)

A Compilation by the

PRE- & POST AWARD SERVICES OFFICE OF RESEARCH, INNOVATION AND DEVELOPMENT (ORID) UNIVERSITY OF GHANA

May 2021

Research Grants

Innovation Grants

Academic-Industry Grants

Collaborative Opportunities

Technology Development Grants



TABLE OF CONTENTS

optional)	20
NIH: Fogarty International Center	20
Closing date: 03 Aug 21	20
DEADLINE BROUGHT FORWARD: Developing digital therapeutics for substantuse disorders (UG3/UH3 clinical trial optional)	
NIH: National Institute on Drug Abuse	20
Closing date: 04 Aug 21	20
Understanding post-transcriptional regulation of intact and defective HIV ribonucleic acid (R61/R33 clinical trial not allowed)	20
NIH: National Institute of Allergy and Infectious Diseases	20
Closing date: 04 Aug 21	20
Research education programme for clinical researchers and clinicians (R25 clinical trial optional)	
NIH: National Institute on Drug Abuse	20
Closing date: 10 Aug 21	20
Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional)	21
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 10 Aug 21	
Device-based treatments for substance use disorders (UG3/UH3 clinical trial optional)	
NIH: National Institute on Drug Abuse	21
Closing date: 10 Aug 21	21
DEADLINE BROUGHT FORWARD: Exploratory studies to investigate mechani of HIV infection, replication, latency or pathogenesis in the context of substantuse disorders (R61/R33 clinical trial not allowed)	ce
NIH: National Institute on Drug Abuse	21
Closing date: 10 Aug 21	
Blueprint neurotherapeutics network – biologic-based drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional)	22
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 10 Aug 21	
OLOUILIS MAKEL IV LIMS #IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	



Cutting-edge basic research awards (R21 clinical trial optional)	22
NIH: National Institute on Drug Abuse	22
Closing date: 10 Aug 21	22
Utilising the PLCO biospecimens resource to bridge gaps in cancer aetiology early-detection research (U01 clinical trial not allowed)	
NIH: National Cancer Institute	22
Closing date: 11 Aug 21	22
NIDA avant-garde award programme for HIV/AIDS and substance use disor research (DP1 clinical trial optional)	
NIH: National Institute on Drug Abuse	22
Closing date: 13 Aug 21	23
Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 clinical trials optional)	
NIH: National Institute on Drug Abuse	23
Closing date: 13 Aug 21	23
Clinical trial readiness for rare neurological and neuromuscular diseases (U clinical trial not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	23
Closing date: 18 Aug 21	23
International research in infectious diseases (R01 clinical trial not allowed) AIDS-related	•
NIH: National Institute of Allergy and Infectious Diseases	23
Closing date: 19 Aug 21	23
Planning grant for Fogarty HIV research training programme for low- and middle-income country institutions (D71)	23
NIH: Fogarty International Center	23
Closing date: 20 Aug 21	24
Fogarty HIV research training programme for low- and middle-income cour institutions (D43 clinical trial optional)	
NIH: Fogarty International Center	24
Closing date: 20 Aug 21	24
Infrastructure development training programmes for critical HIV research a low- and middle-income country institutions (G11 clinical trials not allowed	
NIH: Fogarty International Center	24
Closing date: 20 Aug 21	
BRAIN initiative – standards to define experiments related to the BRAIN initiative (R01 clinical trial not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	24



Closing date: 02 Sep 21	24
BRAIN initiative – proof of concept development of early stage next generation human brain imaging (U01 clinical trial not allowed)	
NIH: National Institute of Biomedical Imaging and Bioengineering	25
Closing date: 03 Sep 21	25
Notice of special interest – small business initiatives for innovative diagnostic technology for improving outcomes for maternal health	
NIH: National Institute of Biomedical Imaging and Bioengineering	25
Closing date: 05 Sep 21	25
HIV infection of the central nervous system (R01 clinical trial not allowed)	25
NIH: National Institute of Neurological Disorders and Stroke	25
Closing date: 07 Sep 21	25
Dissemination and implementation research in health (R21 clinical trial optional): AIDS-related	25
NIH: National Cancer Institute	
Closing date: 07 Sep 21	26
Imaging – science track award for research transition (R03 clinical trial optional): AIDS-related	
NIH: National Institute on Drug Abuse	26
Closing date: 07 Sep 21	
Small research grant programme (parent R03 clinical trial not allowed): AIDS-related	-
NIH: National Human Genome Research Institute	
Closing date: 07 Sep 21	
Exploratory or developmental research grant programme (parent R21 clinical trial not allowed): AIDS-related	l
NIH: National Eye Institute	
Closing date: 07 Sep 21	
NEI research grant for vision related secondary data analysis (R21 clinical tria not allowed): AIDS-related	ıl
NIH: National Eye Institute	
Closing date: 07 Sep 21	
Exploratory/developmental bioengineering research grants (R21 clinical trial optional): AIDS-related	
NIH: National Cancer Institute	
Closing date: 07 Sep 21	
Bioengineering research grants (R01 clinical trial required): AIDS-related	
NIH: National Institute of Biomedical Imaging and Bioengineering	27



Closing date: 07 Sep 21	2/
Research project grant (parent R01 basic experimental studies with humans required): AIDS-related	27
NIH: National Eye Institute	27
Closing date: 07 Sep 21	27
AIDS-science track award for research transition (R03 clinical trial optional).	28
NIH: National Institute on Drug Abuse	28
Closing date: 07 Sep 21	28
Bioengineering research partnerships (U01 clinical trial required): AIDS-relationships	
NIH: National Institute of Biomedical Imaging and Bioengineering	
National Institute of Dental and Craniofacial Research small grant programme for new investigators (R03 clinical trial not allowed): AIDS-related	
NIH: National Institute of Dental and Craniofacial Research Closing date: 07 Sep 21	
NLM research grants in biomedical informatics and data science (R01 clinical trial optional): AIDS-related	
NIH: National Library of Medicine	
Closing date: 07 Sep 21	29
Research to advance vaccine safety (R21 clinical trial not allowed): AIDS-rela	
NIH: National Institute of Allergy and Infectious Diseases	29
Closing date: 07 Sep 21	29
Pilot and feasibility studies in preparation for drug and alcohol abuse preventrials (R34 clinical trial optional): AIDS-related	
NIH: National Institute on Drug Abuse	29
Closing date: 07 Sep 21	29
Drug discovery for nervous system disorders (R21 clinical trial not allowed): AIDS-related	29
NIH: National Institute of Neurological Disorders and Stroke	29
Closing date: 07 Sep 21	29
Drug discovery for nervous system disorders (R01 clinical trials not allowed) AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	29
Closing date: 07 Sep 21	30
Accelerating the pace of drug abuse research using existing data (R01 clinical trial optional): AIDS-related	
NIH: National Institute on Drug Abuse	30



Closing date: 07 Sep 21	30
Alzheimer's drug development programme (U01 clinical trial optional): AIDS related	
NIH: National Institute on Aging	30
Closing date: 07 Sep 21	30
Discovery of in vivo chemical probes for the nervous system (R01 clinical trianot allowed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	30
Closing date: 07 Sep 21	30
Development and testing of novel interventions to improve HIV prevention, cand programme implementation (R34 clinical trial optional)	
NIH: National Institute on Drug Abuse	31
Closing date: 07 Sep 21	31
Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R01 clinical trial optional): AIDS-related	31
NIH: National Cancer Institute	31
Closing date: 07 Sep 21	31
Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R21 clinical trial optional): AIDS-related	31
NIH: National Cancer Institute	
Closing date: 07 Sep 21	31
Dissemination and implementation research in health (R01 clinical trial optional): AIDS-related	
NIH: National Cancer Institute	
Closing date: 07 Sep 21	
Dissemination and implementation research in health (R03 clinical trial not allowed): AIDS-related	
NIH: National Cancer Institute	
Closing date: 07 Sep 21	32
Research education programme for clinical researchers and clinicians (R25 clinical trial optional): AIDS-related	
NIH: National Institute on Drug Abuse	
Closing date: 07 Sep 21	
New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	32
Closing date: 07 Sep 21	32



Eradication of HIV-1 from central nervous system reservoirs (R01 clinical tr	
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 07 Sep 21	
Collaborative clinical vision project – resource centre grant (UG1 clinical tria	
NIH: National Eye Institute	33
Closing date: 07 Sep 21	33
Collaborative clinical vision research – chair's grant (UG1 clinical trial requin	
NIH: National Eye Institute	33
Closing date: 07 Sep 21	33
Collaborative clinical vision research project – coordinating centre grant (UC clinical trial required): AIDS-related	
NIH: National Eye Institute	33
Closing date: 07 Sep 21	34
Innovations in HIV testing, adherence and retention to optimise HIV care continuum outcomes (R01 clinical trial optional)	34
NIH: National Institute of Neurological Disorders and Stroke	34
Closing date: 07 Sep 21	34
Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UH2/UH3 clinical trial optional): AIDS-related	34
NIH: National Institute of Neurological Disorders and Stroke	34
Closing date: 07 Sep 21	
Prevention research in mid-life adults (R21 clinical trial optional): AIDS-rela	
NIH: National Institute of Nursing Research	34
Closing date: 07 Sep 21	34
Prevention research in mid-life adults (R01 clinical trial optional): AIDS-rela	
NIH: National Institute of Nursing Research	35
Closing date: 07 Sep 21	
Maternal nutrition and pre-pregnancy obesity – effects on mothers, infants a children (R01 clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	35
Closing date: 07 Sep 21	35
Developing the therapeutic potential of the endocannabinoid system for pair treatment (R01 clinical trial optional): AIDS-related	



NIH: National Institute on Drug Abuse	35
Closing date: 07 Sep 21	35
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R21 clinical trial optional): AIDS-related	35
NIH: National Institute of Nursing Research	35
Closing date: 07 Sep 21	36
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional): AIDS-related	36
NIH: National Institute of Nursing Research	36
Closing date: 07 Sep 21	36
Small research grants for oral health data analysis and statistical methodology development (R03 clinical trial not allowed): AIDS-related	
NIH: National Institute of Dental and Craniofacial Research	36
Closing date: 07 Sep 21	36
HIV/AIDS high priority drug abuse research (R01 clinical trial optional)	36
NIH: National Institute on Drug Abuse	36
Closing date: 07 Sep 21	37
Innovations in HIV prevention, testing, adherence and retention to optimise H prevention and care continuum outcomes (R21 clinical trial optional)	
NIH: National Institute of Neurological Disorders and Stroke	37
Closing date: 07 Sep 21	
Clinical studies of mental illness (collaborative R01 clinical trial optional): AID related	S-
NIH: National Institute of Neurological Disorders and Stroke	37
Closing date: 07 Sep 21	37
Multidisciplinary studies of HIV/AIDS and ageing (R21 clinical trial optional).	37
NIH: National Institute on Aging	37
Closing date: 07 Sep 21	37
Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional).	38
NIH: National Institute on Aging	38
Closing date: 07 Sep 21	
Discovery of cell-based chemical probes for novel brain targets (R21 clinical transcribed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	38
Closing date: 07 Sep 21	38
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 clinical trial not allowed): AIDS-related	
NIH: National Cancer Institute	38



Closing date: 07 Sep 21	38
Understanding and modifying temporal dynamics of coordinated neural activities (R21 clinical trial optional): AIDS-related	ity 38
NIH: National Institute of Neurological Disorders and Stroke	38
Closing date: 07 Sep 21	39
Understanding and modifying temporal dynamics of coordinated neural activities (R01 clinical trial optional): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	39
Closing date: 07 Sep 21	39
Exploratory or developmental research grant programme (parent R21 clinica trial required): AIDS-related	
NIH: National Eye Institute	39
Closing date: 07 Sep 21	39
NIMH exploratory/developmental research grant (R21 clinical trial not allowed AIDS-related	
NIH: National Institute of Mental Health	39
Closing date: 07 Sep 21	39
Joint NINDS/NIMH exploratory neuroscience research grant (R21 clinical tria optional): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	40
Closing date: 07 Sep 21	40
Research project grant (parent R01 clinical trial not allowed): AIDS-related	40
NIH: National Eye Institute	40
Closing date: 07 Sep 21	40
Cancer prevention and control clinical trials grant programme (R01 clinical trequired): AIDS-related	
NIH: National Cancer Institute	40
Closing date: 07 Sep 21	40
Pilot and feasibility studies of HIV and animal models for HIV infection within mission of the NIDDK (R21 clinical trial not allowed): AIDS-related	
NIH: National Institute of Diabetes and Digestive and Kidney Diseases	40
Closing date: 07 Sep 21	41
Disease mechanisms of prenatal and paediatric hydrocephalus (R01 clinical transcribed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	41
Closing date: 07 Sep 21	41
NIDA small research grant programme (R03 clinical trial required): AIDS-rela	
NIH: National Institute on Drug Abuse	41



Closing date: 07 Sep 21	.41
Tools to enhance the study of prenatal and paediatric hydrocephalus (R21 clinical trial not allowed): AIDS-related	41
NIH: National Institute of Neurological Disorders and Stroke	.41
Closing date: 07 Sep 21	.41
Small research grants for analyses of Gabriella Miller Kids First paediatric research data (R03 clinical trial not allowed): AIDS-related	42
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development	42
Closing date: 07 Sep 21	.42
Precision imaging of oral lesions (R01 clinical trial not allowed): AIDS-related.	42
NIH: National Institute of Dental and Craniofacial Research	42
Closing date: 07 Sep 21	42
Precision imaging of oral lesions (R21 clinical trial not allowed): AIDS-related.	42
NIH: National Institute of Dental and Craniofacial Research	42
Closing date: 07 Sep 21	42
Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R21 clinical trial optional): AIDS related	S-
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development	43
Closing date: 07 Sep 21	.43
Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R01 clinical trial optional): AIDS related	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development	43
Closing date: 07 Sep 21	.43
Investigator-initiated research in computational genomics and data science (R clinical trial not allowed): AIDS-related	
NIH: National Human Genome Research Institute	.43
Closing date: 07 Sep 21	.43
Investigator-initiated research in computational genomics and data science (R clinical trial not allowed): AIDS-related	
NIH: National Human Genome Research Institute	.44
Closing date: 07 Sep 21	.44
Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R01 clinical trial optional): AIDS-related	44
NIH: National Institute on Alcohol Abuse and Alcoholism	.44
Closing date: 07 Sep 21	44



Vision research epidemiology grant (UG1 clinical trial not allowed):	
NIH: National Eye Institute	
Closing date: 07 Sep 21	44
Alcohol and other drug interactions – unintentional injuries and ove epidemiology and prevention (R03 clinical trial optional): AIDS-rela	
NIH: National Institute on Alcohol Abuse and Alcoholism	45
Closing date: 07 Sep 21	45
Alcohol and other drug interactions – unintentional injuries and ove epidemiology and prevention (R21 clinical trial optional): AIDS-rela	
NIH: National Institute on Alcohol Abuse and Alcoholism	45
Closing date: 07 Sep 21	45
Advancing translational and clinical probiotic/prebiotic and human research (R01 clinical trial optional): AIDS-related	
NIH: National Cancer Institute	45
Closing date: 07 Sep 21	45
New computational methods for understanding the functional role of variants that are associated with mental disorders (R01 (collab) clin allowed): AIDS-related	ical trial not
NIH: National Institute of Neurological Disorders and Stroke	46
Closing date: 07 Sep 21	
Applying a biopsychosocial perspective to self-management of chron clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	46
Closing date: 07 Sep 21	46
Biobehavioural basis of chronic pain (R01 clinical trial optional): All	DS-related.46
NIH: National Institute of Nursing Research	46
Closing date: 07 Sep 21	46
Applying a biopsychosocial perspective to self-management of chronclinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	46
Closing date: 07 Sep 21	47
Biobehavioural basis of chronic pain (R21 clinical trial optional): AII	DS-related.47
NIH: National Institute of Nursing Research	47
Closing date: 07 Sep 21	47
Fc-dependent mechanisms of antibody-mediated killing (R21 clinica allowed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 07 Sep 21	



Addressing caregiver symptoms through technological tools (R01 clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	
Closing date: 07 Sep 21	47
Addressing caregiver symptoms through technological tools (R21 clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	48
Closing date: 07 Sep 21	48
Advancing research in augmentative and alternative communication (R01 clinical trial optional): AIDS-related	48
NIH: National Institute on Deafness and other Communication Disorders	48
Closing date: 07 Sep 21	48
End-of-life and palliative care approaches to advanced signs and symptoms (Finical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	48
Closing date: 07 Sep 21	48
Advancing research in augmentative and alternative communication (R21 clinical trial optional): AIDS-related	48
NIH: National Institute on Deafness and other Communication Disorders	48
Closing date: 07 Sep 21	49
End-of-life and palliative care approaches to advanced signs and symptoms (Finical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	49
Closing date: 07 Sep 21	49
Engaging men in HIV testing, prevention and care (R01 clinical trial optional)	49
NIH: National Institute of Allergy and Infectious Diseases	49
Closing date: 07 Sep 21	49
Engaging men in HIV testing, prevention and care (R21 clinical trial optional)	49
NIH: National Institute of Allergy and Infectious Diseases	49
Closing date: 07 Sep 21	49
Strategies to provide culturally tailored palliative and end-of-life care for seriously ill American Indian and Alaska Native individuals (R01 clinical trial optional): AIDS-related	50
NIH: National Institute of Nursing Research	
Closing date: 07 Sep 21	
Strategies to provide culturally tailored palliative and end-of-life care for seriously ill American Indian and Alaska Native individuals (R21 clinical trial	
optional): AIDS-related	
NIH: National Institute of Nursing Research	50



Closing date: 07 Sep 21	50
Processing and presentation of non-conventional MHC ligands (R01 clinical transcribed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	50
Closing date: 07 Sep 21	50
Processing and presentation of non-conventional MHC ligands (R21 clinical transcription): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	50
Closing date: 07 Sep 21	51
Telomeres in wellness and disease – a biobehavioural approach (R01 clinical trial optional): AIDS-related	51
NIH: National Institute of Nursing Research	51
Closing date: 07 Sep 21	
Telomeres in wellness and disease – a biobehavioural approach (R21 clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	51
Closing date: 07 Sep 21	
Exploratory or developmental research grant programme (parent R21 basic experimental studies with humans required): AIDS-related	
NIH: National Eye Institute	51
Closing date: 07 Sep 21	52
Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R01 clinical transcript allowed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	52
Closing date: 07 Sep 21	52
Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R21 clinical transcribed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	52
Closing date: 07 Sep 21	52
Bioengineering research grants (R01 clinical trial not allowed): AIDS-related	52
NIH: National Institute of Biomedical Imaging and Bioengineering	52
Closing date: 07 Sep 21	52
Bioengineering research partnerships (U01 clinical trial not allowed): AIDS-related	
NIH: National Institute of Biomedical Imaging and Bioengineering	
Closing date: 07 Sen 21	53



Exploratory/developmental bioengineering research grants (R21 clinical tria not allowed): AIDS-related	
NIH: National Cancer Institute	
Closing date: 07 Sep 21	53
Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R01 clinical trial not allowed) AIDS-related	:
NIH: National Institute on Drug Abuse	53
Closing date: 07 Sep 21	53
Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R21 clinical trial not allowed) AIDS-related	
NIH: National Institute on Drug Abuse	53
Closing date: 07 Sep 21	54
Comparative effectiveness research in clinical neurosciences (UG3/UH3 clinical not allowed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	54
Closing date: 07 Sep 21	54
Clinical research study planning grant programme (R34 clinical trial not allowed): AIDS-related	54
NIH: National Eye Institute	
Closing date: 07 Sep 21	54
Novel RNAs in virology and immune regulation – basic science and therapeut discovery (R21 clinical trial not allowed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 07 Sep 21	
Discovery of biomarkers and biomarker signatures for neurological and neuromuscular disorders (R61/R33 clinical trial optional): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	55
Closing date: 07 Sep 21	55
Mechanisms of tolerance (R21/R33 clinical trial required): AIDS-related	55
NIH: National Institute on Alcohol Abuse and Alcoholism	55
Closing date: 07 Sep 21	55
Development and application of PET and SPECT imaging ligands as biomarke for drug discovery and for pathophysiological studies of CNS disorders (R01 clinical trial optional): AIDS related	
clinical trial optional): AIDS-relatedNIH: National Institute of Neurological Disorders and Stroke	
Closing date: 07 Sep 21	
VIVI 1116 VIII VII VII VII VII VII VII VII VII V	1. 1



for drug discovery and for pathophysiological studies of central nervous syste disorders (R01 clinical trial not allowed): AIDS-related	em
NIH: National Institute of Neurological Disorders and Stroke	56
Closing date: 07 Sep 21	56
Catalytic tool and technology development in kidney, urological and haematological diseases (R21 clinical trial not allowed): AIDS-related	56
NIH: National Institute of Diabetes and Digestive and Kidney Diseases	56
Closing date: 07 Sep 21	56
Research project grant (parent R01 clinical trial required): AIDS-related	56
NIH: National Eye Institute	56
Closing date: 07 Sep 21	56
HEAL initiative – non-addictive analgesic therapeutics development to treat p (UG3/UH3 clinical trial not allowed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	56
Closing date: 07 Sep 21	57
Notice of special interest – telehealth strategies for individuals with HIV and substance use disorders	57
NIH: National Institute on Drug Abuse	57
Closing date: 07 Sep 21	57
Blueprint neurotherapeutics network – biologic-based drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional): AIDS-related	57
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 07 Sep 21	
Single-site investigator-initiated clinical trials (R61/R33 clinical trial required AIDS-related	d):
NIH: National Heart, Lung and Blood Institute	57
Closing date: 08 Sep 21	
Clinical coordinating centre for multi-site investigator-initiated clinical trials (collaborative UG3/UH3 clinical trial required): AIDS-related	
NIH: National Heart, Lung and Blood Institute	58
Closing date: 08 Sep 21	
Data coordinating centre for multi-site investigator-initiated clinical trials (collaborative U24 clinical trial required): AIDS-related	
NIH: National Heart, Lung and Blood Institute	58
Closing date: 08 Sep 21	
Developing digital therapeutics for substance use disorders (UG3/UH3 clinica trial optional): Aids-related	



NIH: National Institute on Drug Abuse	58
Closing date: 08 Sep 21	58
Systems approach to understand mechanisms of heterogeneous response to influenza (R01 clinical trial not allowed)	59
NIH: National Institute of Allergy and Infectious Diseases	59
Closing date: 08 Sep 21	59
NIAID clinical trial implementation cooperative agreement (U01 clinical trial required)	
NIH: National Institute of Allergy and Infectious Diseases	59
Closing date: 13 Sep 21	59
NIAID clinical trial planning grant (R34 clinical trial not allowed)	59
NIH: National Institute of Allergy and Infectious Diseases	59
Closing date: 14 Sep 21	59
BRAIN initiative – theories, models and methods for analysis of complex data from the brain (R01 clinical trial not allowed)	
NIH: National Institute of Biomedical Imaging and Bioengineering	59
Closing date: 14 Sep 21 (Forecast)	60
Genetic architecture of mental disorders in ancestrally diverse populations (Uclinical trial not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	60
Closing date: 15 Sep 21	60
Genetic architecture of mental disorders in ancestrally diverse populations (collaborative U01 clinical trial not allowed)	60
NIH: National Institute of Neurological Disorders and Stroke	60
Closing date: 15 Sep 21	60
Blueprint for neuroscience research – tools and technologies to explore nervo system biomolecular condensates (R21 clinical trial not allowed)	
NIH: National Institute on Drug Abuse	60
Closing date: 15 Sep 21	60
High-throughput discovery and validation of novel signal transducers or smal molecules that modulate opioid or other substance use disorder relevant pathways (R01 – clinical trials not allowed)	
NIH: National Institute on Drug Abuse	61
Closing date: 15 Sep 21	61
Mechanism-focused research to promote adherence to healthful behaviours to prevent mild cognitive impairment and Alzheimer's disease and related dementias (R01 clinical trial optional)	
NIH: National Institute on Aging	
Closing date: 15 Sep 21	61



prevent mild cognitive impairment and Alzheimer's disease and related	:0
dementias (R61/R33 clinical trial required)	61
NIH: National Institute on Aging	61
Closing date: 15 Sep 21	61
Clinical characterisation of cancer therapy-induced adverse sequelae and mechanism-based interventional strategies (R01 clinical trial optional)	62
NIH: National Cancer Institute	62
Closing date: 20 Sep 21	62
Biomedical knowledgebase (U24 clinical trials not allowed)	62
NIH: National Institute of General Medical Sciences	62
Closing date: 24 Sep 21	62
Biomedical data repository (U24 – clinical trials not allowed)	62
NIH: National Institute of General Medical Sciences	62
Closing date: 24 Sep 21	62
Novel synthetic nucleic acid technology development (R01 clinical trial not allowed)	62
NIH: National Human Genome Research Institute	62
Closing date: 01 Oct 21	62
Novel synthetic nucleic acid technology development (R21 clinical trial not allowed)	63
NIH: National Human Genome Research Institute	
Closing date: 01 Oct 21	
Limited competition – modular budget research project grant for NIH nurse scientist scholars (R01 clinical trial optional)	
NIH: National Institute of Nursing Research	
Closing date: 04 Oct 21	
Identification of positive valence system related targets for novel suicide prevention approaches (R01 clinical trial optional)	63
NIH: National Institute of Mental Health	63
Closing date: 05 Oct 21	63
Ethical issues in translational science research (R01 clinical trial optional)	
NIH: National Center for Advancing Translational Sciences	63
Closing date: 06 Oct 21	
BRAIN initiative – development and validation of novel tools to probe cell-specific and circuit-specific processes in the brain (R01 clinical trial not allow	/ed)
NIH: National Institute of Mental Health	
Closing date: 08 Oct 21	64



Secondary analyses of existing datasets of tobacco use and health (R21 clinicatrial not allowed)	
NIH: National Cancer Institute	
Closing date: 08 Oct 21	
Maximising the scientific value of existing biospecimen collections (R21 clinic trial not allowed)	cal
NIH: National Cancer Institute	64
Closing date: 08 Oct 21	64
COMING SOON: Secondary analyses of existing datasets of tobacco use and he (R21 clinical trial not allowed)	64
NIH: Office of the Director	
Closing date: 08 Oct 21 (Forecast)	65
Extracellular RNA carrier subclasses in processes relevant to substance use disorders or HIV infection (R01 clinical trial not allowed)	65
NIH: National Institute on Drug Abuse	65
Closing date: 13 Oct 21	65
Extracellular RNA carrier subclasses in processes relevant to substance use disorders or HIV infection (R21 clinical trial not allowed)	65
NIH: National Institute on Drug Abuse	65
Closing date: 13 Oct 21	65
Exploratory clinical neuroscience research on substance use disorders (R61/clinical trial optional)	
NIH: National Institute on Drug Abuse	
Closing date: 13 Oct 21	66
Administrative supplements for research on dietary supplements (admin sup clinical trial not allowed)	•
NIH: National Institutes of Health	66
Closing date: 15 Oct 21	66
BRAIN initiative – integration and analysis of BRAIN initiative data (R01 clini trial not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	66
Closing date: 15 Oct 21	66
Understanding and reducing cardiovascular disease in type 1 diabetes mellitu (R01 – clinical trial optional)	
NIH: National Heart, Lung and Blood Institute	66
Closing date: 15 Oct 21	66
Identification of positive valence system related targets for novel suicide prevention approaches (R21 clinical trial optional)	67
NIH: National Institute of Mental Health	67



Closing date: 16 Oct 2167
BRAIN initiative – pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 clinical trial not allowed)67
NIH: National Institute of Neurological Disorders and Stroke67
Closing date: 19 Oct 2167
Development of new technologies and bioengineering solutions for the advancement of cell replacement therapies for type 1 diabetes (R01 clinical trial optional)67
NIH: National Institute of Diabetes and Digestive and Kidney Diseases67
Closing date: 20 Oct 2167
Advancing technologies to improve delivery of pharmacological, gene editing and other cargoes for HIV and substance use disorders mechanistic or therapeutic research (R01 clinical trial optional)
NIH: National Institute on Drug Abuse68
Closing date: 25 Oct 2168
Secondary analysis of existing datasets in heart, lung and blood diseases and sleep disorders (R21 clinical trial not allowed)68
NIH: National Heart, Lung and Blood Institute68
Closing date: 28 Oct 2168
BRAIN initiative – new concepts and early-stage research for large-scale recording and modulation in the nervous system (R21 clinical trial not allowed)
NIH: National Eye Institute68
Closing date: 29 Oct 2168



Global infectious disease research training programme (D43 clinical trial optional)


NIH: Fogarty International Center

This supports collaborative training programmes that will strengthen the capacity of a low- and middle income country institution to conduct infectious disease research. Awards

are worth up to USD 276,000 for up to five years.

Closing date: 03 Aug 21

Link to *Research Professional



NIH: National Institute on Drug Abuse

This call supports research projects to accelerate the development of digital therapeutics to treat substance use disorders. Awards are worth USD 500,000 in direct costs per year over three years.

Closing date: 04 Aug 21

Link to *Research Professional

<u>Understanding post-transcriptional regulation of intact and defective HIV ribonucleic acid (R61/R33 clinical trial not allowed)</u>

NIH: National Institute of Allergy and Infectious Diseases

This supports research focusing on the understanding of posttranscriptional regulation of intact and defective HIV ribonucleic acid. The maximum project period is five years.

Closing date: 04 Aug 21

Link to *Research Professional

Research education programme for clinical researchers and clinicians (R25 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports educational activities that complement or enhance training in biomedical, behavioural and clinical research. Grants are

worth up to USD 350,000 per year for up to five years.

Closing date: 10 Aug 21



Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke

This supports neuroscience investigators seeking to advance their small molecule drug discovery and development projects into the clinic. The maximum project period

is one year in the UG3 phase and four years in the UH3 phase.

Closing date: 10 Aug 21

Link to *Research Professional

<u>Device-based treatments for substance use disorders</u> (UG3/UH3 clinical trial optional)

NIH: National Institute on Drug Abuse

This aims to accelerate the development of devices to treat substance use disorders. Budgets are limited to USD 500,000 direct costs for the entire UG3 phase, but are not limited for the UH3 phase. The

project period is limited to two years for the UG3 phase and three years for the UH3 phase.

Closing date: 10 Aug 21

Link to *Research Professional

<u>DEADLINE BROUGHT FORWARD: Exploratory studies to</u>
<u>investigate mechanisms of HIV infection, replication, latency</u>
<u>or pathogenesis in the context of substance use disorders</u>
(R61/R33 clinical trial not allowed)

NIH: National Institute on Drug Abuse

This call supports research investigating the underlying molecular mechanisms by which HIV infection is initiated, established and maintained in the central nervous system. Funding is worth up to USD

2.2 million per project over five years.

Closing date: 10 Aug 21



Blueprint neurotherapeutics network – biologic-based drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke

This supports preclinical discovery and development of potential therapeutic biotechnology products and biologics, gene-based therapies, cell therapies and novel emerging therapies. The maximum project period is five years.

Closing date: 10 Aug 21

Link to *Research Professional

Cutting-edge basic research awards (R21 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports high-risk and potentially high-impact research that is underrepresented or not included in National Institute Drug Abuse's current portfolio that has the potential to transform substance

abuse disorder research. Grants are worth up to USD 275,000 for a maximum period of two years.

Closing date: 10 Aug 21

Link to *Research Professional

Utilising the PLCO biospecimens resource to bridge gaps in cancer aetiology and early-detection research (U01 clinical trial not allowed)

NIH: National Cancer Institute

This supports research in cancer aetiology and early-detection biomarkers, using the biorepository resources of the National Caner Institute-sponsored prostate, lung, colorectal and ovarian cancer

screening trial. Application budgets are not limited. The maximum project period is five years.

Closing date: 11 Aug 21

Link to *Research Professional

NIDA avant-garde award programme for HIV/AIDS and substance use disorder research (DP1 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports scientists who propose high impact research that will open new areas of HIV/AIDS research relevant to substance use

disorders or lead to new avenues for prevention and treatment of HIV/AIDS in people who use drugs.



Grants are worth up to USD 700,000 each per year for up to five years.

Closing date: 13 Aug 21

Link to *Research Professional

Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 clinical trials optional)

NIH: National Institute on Drug Abuse

This supports projects that further develop or exploit advances using in situ or in vivo imaging or related technologies. Funding is worth up to USD 2.05 million for a maximum of five years.

Closing date: 13 Aug 21

Link to *Research Professional

Clinical trial readiness for rare neurological and neuromuscular diseases (U01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. Grants are worth up to USD 650,000 each per year over five years.

Closing date: 18 Aug 21

Link to *Research Professional

<u>International research in infectious diseases (R01 clinical trial not allowed): AIDS-related</u>

NIH: National Institute of Allergy and Infectious Diseases

This AIDS-related funding opportunity supports high-priority, regionally-relevant infectious disease research by international investigators in resource-restrained countries. Grants are worth up to

USD 125,000 per year for a maximum period of a five years.

Closing date: 19 Aug 21

Link to *Research Professional

Planning grant for Fogarty HIV research training programme for low- and middle-income country institutions (D71)

NIH: Fogarty International Center



This supports research training that strengthens HIV research capacity of institutions in low-and middleincome countries. Application budgets are limited to USD 28,000 per year for a maximum of two years.

Closing date: 20 Aug 21

Link to *Research Professional

Fogarty HIV research training programme for low- and middle-income country institutions (D43 clinical trial optional)

NIH: Fogarty International Center

This aims to strengthen the scientific capacity of institutions in low- and middle-income countries to conduct HIV research relevant to the evolving HIV epidemic in their country. Application budgets are

limited to USD 280,000 per year for up to five years.

Closing date: 20 Aug 21

Link to *Research Professional

Infrastructure development training programmes for critical HIV research at low- and middle-income country institutions (G11 clinical trials not allowed)

NIH: Fogarty International Center

This aims to strengthen the scientific capacity of institutions in low- and middle-income countries to conduct HIV research on the evolving HIV epidemic in their countries.

Application budgets are limited to

USD 92,000 per year for a maximum period of three years.

Closing date: 20 Aug 21

Link to *Research Professional

BRAIN initiative – standards to define experiments related to the BRAIN initiative (R01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports the development of data standards that describe experimental protocols that are being conducted as part of the BRAIN initiative. The maximum project period is two years.

Closing date: 02 Sep 21



BRAIN initiative – proof of concept development of early stage next generation human brain imaging (U01 clinical trial not allowed)

NIH: National Institute of Biomedical Imaging and Bioengineering

This supports the early-stage development of entirely new or next generation non-invasive human brain imaging tools and methods that lead to transformative advances in the understanding of the human

brain. Grants are worth up to USD 300,000 per year for up to two years.

Closing date: 03 Sep 21

Link to *Research Professional

Notice of special interest – small business initiatives for innovative diagnostic technology for improving outcomes for maternal health

NIH: National Institute of Biomedical Imaging and Bioengineering

This aims to encourage interest in the small business community to develop various approaches, technologies and tools to address the health issues of maternal morbidity.

Closing date: 05 Sep 21

Link to *Research Professional

HIV infection of the central nervous system (R01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports research projects that focus on delineating the pathophysiology of HIV-1 associated central nervous system disease in the setting of chronic viral suppression and antiretroviral

therapy. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Dissemination and implementation research in health (R21 clinical trial optional): AIDS-related</u>

NIH: National Cancer Institute

This supports AIDS-related innovative approaches to identifying and developing strategies to

disseminate and implement evidence-based practices into public public health, clinical practice and



community settings. Grants are worth up to USD 275,000 each for two years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Imaging – science track award for research transition (R03</u> clinical trial optional): AIDS-related

NIH: National Institute on Drug Abuse

This AIDS-related announcement facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to enable them to

conduct small proof of concept studies. Awards are worth up to USD 150,000 for a maximum period of one year.

Closing date: 07 Sep 21

Link to *Research Professional

Small research grant programme (parent R03 clinical trial not allowed): AIDS-related

NIH: National Human Genome Research Institute

This supports small AIDS-related research projects that can be carried out in a short period of time with limited resources. Awards are worth

up to USD 50,000 in direct costs per year for up to two years.

Closing date: 07 Sep 21

Link to *Research Professional

Exploratory or developmental research grant programme (parent R21 clinical trial not allowed): AIDS-related

NIH: National Eye Institute

This AIDS-related funding opportunity supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Application budgets are

limited to USD 275,000 for a twoyear period, with no more than USD 200,000 in any year.

Closing date: 07 Sep 21



NEI research grant for vision related secondary data analysis (R21 clinical trial not allowed): AIDS-related

NIH: National Eye Institute

This AIDS-related opportunity supports vision-related secondary data analyses utilising existing database resources. Grants are worth up to to USD 275,000 for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

Exploratory/developmental bioengineering research grants (R21 clinical trial optional): AIDS-related

NIH: National Cancer Institute

This AIDS-related call supports the demonstration of feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical or

clinical research, clinical care delivery or accessibility. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 07 Sep 21

Link to *Research Professional

Bioengineering research grants (R01 clinical trial required): AIDS-related

NIH: National Institute of Biomedical Imaging and Bioengineering

These AIDS-related grants support collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to the solution of a

biomedical problem. Grants are for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

Research project grant (parent R01 basic experimental studies with humans required): AIDS-related

NIH: National Eye Institute

This supports a discrete, specified, circumscribed AIDS-related project in areas representing the specific interests and competencies of the

investigators. The maximum project period is five years.

Closing date: 07 Sep 21



AIDS-science track award for research transition (R03 clinical trial optional)

NIH: National Institute on Drug Abuse

This seeks to facilitate the entry of both newly independent and earlycareer investigators to the area of drug abuse research on HIV/AIDS. Awards are each worth up to USD 100,000 per year for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

Bioengineering research partnerships (U01 clinical trial required): AIDS-related

NIH: National Institute of Biomedical Imaging and Bioengineering

This AIDS-related funding opportunity encourages bioengineering applications that will accelerate the development and adoption of tools and technologies that can address important

biomedical problems. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

National Institute of Dental and Craniofacial Research small grant programme for new investigators (R03 clinical trial not allowed): AIDS-related

NIH: National Institute of Dental and Craniofacial Research

This AIDS-related opportunity supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research.

Grants are worth up to USD 200,000 over a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

NLM research grants in biomedical informatics and data science (R01 clinical trial optional): AIDS-related

NIH: National Library of Medicine

This AIDS-related opportunity supports innovative research and development in biomedical informatics and data science. Grants

are worth up to USD 250,000 each per year over a maximum period of four years.



Closing date: 07 Sep 21

Link to *Research Professional

Research to advance vaccine safety (R21 clinical trial not allowed): AIDS-related

NIH: National Institute of Allergy and Infectious Diseases

This AIDS-related funding opportunity supports research that will contribute to the overall understanding of vaccine safety.

Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Pilot and feasibility studies in preparation for drug and alcohol</u> <u>abuse prevention trials (R34 clinical trial optional): AIDS-</u> related

NIH: National Institute on Drug Abuse

This AIDS-related opportunity supports research that provides intervention pilot or feasibility data serving as a prerequisite for subsequent applications for larger scale drug or alcohol abuse prevention or drug- or alcohol-

related HIV prevention intervention studies. Grants are worth up to USD 450,000 each over three years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Drug discovery for nervous system disorders (R21 clinical trial</u> not allowed): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related call supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Grants

are worth up to USD 275,000 each over two years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Drug discovery for nervous system disorders (R01 clinical trials not allowed): AIDS-related</u>

NIH: National Institute of Neurological Disorders and Stroke



This AIDS-related funding opportunity supports the discovery of novel compounds for the prevention and treatment of nervous

system disorders. Funding is for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

Accelerating the pace of drug abuse research using existing data (R01 clinical trial optional): AIDS-related

NIH: National Institute on Drug Abuse

This AIDS-related opportunity supports the innovative analysis of existing social science, behavioural, administrative and neuroimaging data to study the aetiology and epidemiology of drug-using behaviours and related disorders,

prevention of drug use and HIV and health service use. Grants are worth up to USD 499,999 per year over a maximum period of five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Alzheimer's drug development programme (U01 clinical trial</u> optional): AIDS-related

NIH: National Institute on Aging

This AIDS-related opportunity supports preclinical and early stage clinical development of small-molecule and biologic therapeutic agents that prevent Alzheimer's disease, slow its progression or treat its cognitive and behavioural

symptoms. Funding is worth up to USD 1 million per project per year for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Discovery of in vivo chemical probes for the nervous system</u> (R01 clinical trial not allowed): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports research on in vivo chemical probes for novel brain targets. Projects may last up to four years.

Closing date: 07 Sep 21



Development and testing of novel interventions to improve HIV prevention, care and programme implementation (R34 clinical trial optional)


NIH: National Institute on Drug Abuse

This supports formative research, intervention development and pilottesting of HIV interventions among populations where substance use may be a contributing factor. Grants

are worth up to USD 450,000 each over three years.

Closing date: 07 Sep 21

Link to *Research Professional



NIH: National Cancer Institute

This encourages transdisciplinary and translational AIDS-related research that will identify the specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Funding is for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R21 clinical trial optional): AIDS-related

NIH: National Cancer Institute

This AIDS-related opportunity supports transdisciplinary and translational research that will identify the specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis

and survival. Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Dissemination and implementation research in health (R01 clinical trial optional): AIDS-related</u>

NIH: National Cancer Institute



This supports innovative AIDSrelated approaches that aim to identify and develop strategies to disseminate and implement evidence-based practices into public health, clinical practice, and community settings. Application budgets are not limited. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Dissemination and implementation research in health (R03</u> clinical trial not allowed): AIDS-related

NIH: National Cancer Institute

This AIDS-related announcement supports innovative approaches to identifying, understanding and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based

interventions, tools, policies and guidelines. Grants are worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional



NIH: National Institute on Drug Abuse

This AIDS-related call supports educational activities that complement and enhance the training of a workforce to meet the nation's biomedical, behavioural and clinical research needs. Grants are

worth up to USD 350,000 per year for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with

mental disorders. The maximum project period is five years.

Closing date: 07 Sep 21



<u>Eradication of HIV-1 from central nervous system reservoirs</u> (R01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system in the context of viral suppression. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Collaborative clinical vision project – resource centre grant</u> (UG1 clinical trial required): AIDS-related

NIH: National Eye Institute

This AIDS-related call supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource or safety-risk clinical trials. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Collaborative clinical vision research – chair's grant (UG1</u> clinical trial required): AIDS-related

NIH: National Eye Institute

This AIDS-related call supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. Application

budgets are not limited, but must reflect the actual needs of the project.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Collaborative clinical vision research project – coordinating</u> centre grant (UG1 clinical trial required): AIDS-related

NIH: National Eye Institute



This AIDS-related funding opportunity supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other demanding

clinical trials. Funding is for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

Innovations in HIV testing, adherence and retention to optimise HIV care continuum outcomes (R01 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke

This supports innovative research to optimise HIV prevention and care. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UH2/UH3 clinical trial optional): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related funding opportunity supports neuroscience investigators seeking to advance their small molecule drug discovery and development projects into the clinic. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Prevention research in mid-life adults (R21 clinical trial optional)</u>: AIDS-related

NIH: National Institute of Nursing Research

This AIDS-related funding opportunity supports research on mid-life adults, those between 50 and 64 years of age, that can inform efforts to optimise health and wellness as individuals age and

prevent illness and disability in later years. Grants are worth up to USD 275,000 for up to two years.

Closing date: 07 Sep 21



<u>Prevention research in mid-life adults (R01 clinical trial</u> optional): AIDS-related

NIH: National Institute of Nursing Research

This AIDS-related opportunity supports research on mid-life adults, between 50 and 64 years of age, that can inform efforts to optimise health and wellness as individuals age, and

prevent illness and disability in later years. Funding is for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Maternal nutrition and pre-pregnancy obesity – effects on mothers, infants and children (R01 clinical trial optional):</u> AIDS-related

NIH: National Institute of Nursing Research

This AIDS-related funding opportunity encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Developing the therapeutic potential of the endocannabinoid</u> <u>system for pain treatment (R01 clinical trial optional): AIDS-</u> related

NIH: National Institute on Drug Abuse

This AIDS-related opportunity supports projects that seek to elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based

therapies for pain. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

End-of-life and palliative needs of adolescents and young adults with serious illnesses (R21 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research



This AIDS-related announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 07 Sep 21

Link to *Research Professional

End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This AIDS-related opportunity supports research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses.

Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Small research grants for oral health data analysis and statistical methodology development (R03 clinical trial not allowed): AIDS-related

NIH: National Institute of Dental and Craniofacial Research

This AIDS-related opportunity supports research projects that involve secondary data analyses of existing oral or craniofacial database resources, or the development of needed statistical methodology for analysing oral and craniofacial data

using existing oral or craniofacial databases. Funding is worth up to USD 200,000 per project over two years.

Closing date: 07 Sep 21

Link to *Research Professional

HIV/AIDS high priority drug abuse research (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports high priority research relevant to drug abuse and HIV and AIDS. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.



Closing date: 07 Sep 21

Link to *Research Professional

Innovations in HIV prevention, testing, adherence and retention to optimise HIV prevention and care continuum outcomes (R21 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke

This encourages research in formative basic behavioural and social science to better understand a single step or steps in the HIV prevention or care continuum, or the initial development and pilot testing of innovative intervention

approaches. Application budgets are limited to USD 275,000 for up to two years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Clinical studies of mental illness (collaborative R01 clinical trial optional)</u>: AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related funding opportunity supports collaborative clinical studies that do not involve treatment development, efficacy or

effectiveness trials. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Multidisciplinary studies of HIV/AIDS and ageing (R21 clinical trial optional)

NIH: National Institute on Aging

This supports studies that aim to improve understanding of aspects of ageing through the lens of HIV infection and its treatment, as well as improve approaches for testing of HIV infection and management of HIV-related complications in

different populations and cultural settings. Awards are worth up to USD 275,000 each for two years.

Closing date: 07 Sep 21



Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional)

NIH: National Institute on Aging

This supports studies addressing HIV and ageing that aim to improve understanding of biological, clinical and socio-behavioural aspects of ageing through the lens of HIV infection. Application budgets are not limited but need to reflect the

actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Discovery of cell-based chemical probes for novel brain</u> <u>targets (R21 clinical trial not allowed): AIDS-related</u>

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. Grants are worth up to USD 275,000 over a two-year period.

Closing date: 07 Sep 21

Link to *Research Professional

Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 clinical trial not allowed): AIDS-related

NIH: National Cancer Institute

This supports AIDS-related research in discovery and development of novel, small molecules for their potential use in studying disease treatment, and to generate new insight into the biology of relevant diseases and processes that are not yet drug targets. The maximum project perios is four years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Understanding and modifying temporal dynamics of</u> <u>coordinated neural activity (R21 clinical trial optional): AIDS-</u> related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related call supports projects that test whether modifying

electrophysiological patterns during behaviour can improve cognitive,



affective, or social processing. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Understanding and modifying temporal dynamics of</u> <u>coordinated neural activity (R01 clinical trial optional): AIDS-</u> related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related call supports research to lay the groundwork for developing systems-level neuroscience interventions into treatments for cognitive, affective or social deficits in psychiatric disorders. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Exploratory or developmental research grant programme (parent R21 clinical trial required): AIDS-related

NIH: National Eye Institute

This supports AIDS-related exploratory and developmental research projects in their early and conceptual stages. Awards are worth

up to USD 275,000 in direct costs for up to two years.

Closing date: 07 Sep 21

Link to *Research Professional

NIMH exploratory/developmental research grant (R21 clinical trial not allowed): AIDS-related

NIH: National Institute of Mental Health

This AIDS-related funding opportunity supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects.

Grants are worth up to USD 275,000 over two years.

Closing date: 07 Sep 21



Joint NINDS/NIMH exploratory neuroscience research grant (R21 clinical trial optional): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related announcement supports exploratory and innovative research projects, which fall within the mission of the National Institute of Neurological Disorders and Stroke and the National Institute of Mental Health. Grants are worth up to USD 275,000 for two years.

Closing date: 07 Sep 21

Link to *Research Professional

Research project grant (parent R01 clinical trial not allowed): AIDS-related

NIH: National Eye Institute

This supports a discrete, specified and circumscribed AIDS-related project in areas representing the specific interests and competencies of the investigators. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Cancer prevention and control clinical trials grant programme</u> (R01 clinical trial required): AIDS-related

NIH: National Cancer Institute

This AIDS-related announcement supports investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life or

survivorship related to cancer. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Pilot and feasibility studies of HIV and animal models for HIV infection within the mission of the NIDDK (R21 clinical trial not allowed): AIDS-related</u>

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This AIDS-related opportunity supports basic and translational research projects examining HIV

infection, persistence, and comorbidities relevant to the the institute's study of diabetes and



other endocrine and metabolic diseases. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Disease mechanisms of prenatal and paediatric hydrocephalus</u> (R01 clinical trial not allowed): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related funding opportunity supports hypothesis-driven research of prenatal and paediatric hydrocephalus.

Application hydrots are not limited.

Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

NIDA small research grant programme (R03 clinical trial required): AIDS-related

NIH: National Institute on Drug Abuse

This supports small clinical trials that can be carried out in a short period of time with limited resources. Grants are worth up to USD 50,000 each per year for up to two years.

Closing date: 07 Sep 21

Link to *Research Professional

Tools to enhance the study of prenatal and paediatric hydrocephalus (R21 clinical trial not allowed): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related funding opportunity supports research that develops or substantially modifies existing cutting-edge tools that will advance prenatal or paediatric hydrocephalus research. Funding is

worth up to USD 275,000 over two years.

Closing date: 07 Sep 21



Small research grants for analyses of Gabriella Miller Kids First paediatric research data (R03 clinical trial not allowed): AIDS-related

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports meritorious small AIDS-related research projects that involve analyses of genomic, phenotypic or clinical datasets that are part of the Kids First programme, and projects that develop approaches, tools or

algorithms to support or enhance analyses of these data. Grants are worth up to USD 200,000 each over two years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Precision imaging of oral lesions (R01 clinical trial not allowed)</u>: AIDS-related

NIH: National Institute of Dental and Craniofacial Research

This AIDS-related opportunity supports the development, adaptation, optimisation and validation of accurate, reproducible, specific and sensitive imaging approaches to improve diagnosis, treatment and treatment monitoring

for diseases and conditions in the oral cavity and oropharynx. Funding is for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Precision imaging of oral lesions (R21 clinical trial not allowed)</u>: AIDS-related

NIH: National Institute of Dental and Craniofacial Research

This supports early-stage AIDS-related research projects that propose to adapt, optimise and validate existing imaging systems or develop new image-based methodologies and analytic tools capable of improving early

detection, diagnosis and targeted treatment of oral diseases and conditions. Grants are worth up to USD 275,000 each over two years.

Closing date: 07 Sep 21



Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R21 clinical trial optional): AIDS-related

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This AIDS-related opportunity supports research on the role of the gut microbiome in regulating metabolism and reproduction and its impact on fertility status with a

focus on AIDS. Grants are worth up to USD 275,000 for up to two years.

Closing date: 07 Sep 21

Link to *Research Professional

Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R01 clinical trial optional): AIDS-related

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This AIDS-related opportunity supports research related to the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal, hypothalamo-pituitary-adrenal and hypothalamo-pituitary-thyroid axes

in the brain. Budgets are limited to USD 499,999 in direct costs per year for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Investigator-initiated research in computational genomics and</u> data science (R01 clinical trial not allowed): AIDS-related

NIH: National Human Genome Research Institute

This AIDS-related opportunity supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of

software and tools of high value to the biomedical genomics community. Funding is for up to five years.

Closing date: 07 Sep 21



Investigator-initiated research in computational genomics and data science (R21 clinical trial not allowed): AIDS-related

NIH: National Human Genome Research Institute

This AIDS-related opportunity supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to

the biomedical genomics community. Direct costs are limited to USD 275,000 over a two-year project period.

Closing date: 07 Sep 21

Link to *Research Professional

Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R01 clinical trial optional): AIDS-related

NIH: National Institute on Alcohol Abuse and Alcoholism

This AIDS-related opportunity supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of

alcohol or drugs singly or in combination. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Vision research epidemiology grant (UG1 clinical trial not allowed): AIDS-related</u>

NIH: National Eye Institute

This supports AIDS-related epidemiologic studies that use creative and innovative approaches to studying vision diseases and disorders with high public impact, to inform prevention and treatment

strategies as well as basic sciences research. Funding is for up to five years.

Closing date: 07 Sep 21



<u>Alcohol and other drug interactions – unintentional injuries</u> <u>and overdoses – epidemiology and prevention (R03 clinical</u> trial optional): AIDS-related

NIH: National Institute on Alcohol Abuse and Alcoholism

This AIDS-related opportunity supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of

alcohol or drugs singly or in combination. Grants are each worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R21 clinical trial optional): AIDS-related

NIH: National Institute on Alcohol Abuse and Alcoholism

This AIDS-related opportunity supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of

alcohol or drugs singly or in combination. Grants are each worth up to USD 275,000 for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

Advancing translational and clinical probiotic/prebiotic and human microbiome research (R01 clinical trial optional): AIDS-related

NIH: National Cancer Institute

This AIDS-related opportunity supports translational and clinical studies using a variety of probiotic and prebiotic carriers to generate measurable functional evidence for the safe and effective use of these carriers in maintaining health or

preventing and treating diseases. The maximum project period is five years.

Closing date: 07 Sep 21



New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 (collab) clinical trial not allowed): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex

aetiologies identified through genome-wide association or sequencing studies. Funding is for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

Applying a biopsychosocial perspective to self-management of chronic pain (R01 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This supports the applications of a biopsychosocial perspective to self-management of chronic pain with a focus on AIDS. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Biobehavioural basis of chronic pain (R01 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This AIDS-related opportunity supports studies on the biobehavioural basis of chronic pain with a focus on the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional

components that underpin the individual's chronic pain experience. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Applying a biopsychosocial perspective to self-management of chronic pain (R21 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This supports the applications of a biopsychosocial perspective to self-



management of chronic pain with a focus on AIDS. Grants are worth up to USD 275,000 for two years.

Closing date: 07 Sep 21

Link to *Research Professional

Biobehavioural basis of chronic pain (R21 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This supports AIDS-related research that focuses on the individual phenotype, genotype and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience.

Grants are worth up to USD 275,000 each over a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Fc-dependent mechanisms of antibody-mediated killing (R21 clinical trial not allowed): AIDS-related</u>

NIH: National Institute of Allergy and Infectious Diseases

This supports AIDS-related research that aims to improve the understanding of Fc-dependent, antibody-mediated killing of pathogen-infected or otherwise dysregulated host cells. Grants are

each worth up to USD 275,000 over a maximum of two years.

Closing date: 07 Sep 21

Link to *Research Professional

Addressing caregiver symptoms through technological tools (R01 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This supports the development and testing of tools to address symptoms in caregivers, regardless of patient symptoms or conditions, with a

focus on AIDS. The project may last up to five years.

Closing date: 07 Sep 21



Addressing caregiver symptoms through technological tools (R21 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This supports AIDS-related research focused on the development and testing of tools to address symptoms in caregivers, regardless of patient symptoms or conditions. Grants are

worth up to USD 275,000 each over a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

Advancing research in augmentative and alternative communication (R01 clinical trial optional): AIDS-related

NIH: National Institute on Deafness and other Communication Disorders

This AIDS-related funding opportunity supports research on augmentative and alternative communication to advance scientific knowledge in the evaluation and treatment of individuals with complex communication needs or

with severe speech and physical impairments. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

End-of-life and palliative care approaches to advanced signs and symptoms (R01 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This AIDS-related funding opportunity supports the examination of the multi-dimentional foundation, experiences and management of complex, advanced signs and symptoms at the

end of life. The project may last up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

Advancing research in augmentative and alternative communication (R21 clinical trial optional): AIDS-related

NIH: National Institute on Deafness and other Communication Disorders

This AIDS-related funding opportunity supports research on augmentative and alternative communication to advance scientific knowledge in the evaluation and

treatment of individuals with complex communication needs or with severe speech and physical impairments. Grants are worth up to



USD 275,000 for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

End-of-life and palliative care approaches to advanced signs and symptoms (R21 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This AIDS-related funding opportunity supports the examination of the multi-dimentional foundation, experiences and management of complex, advanced signs and symptoms at the

end of life. Grants are worth up to USD 275,000 each over a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

Engaging men in HIV testing, prevention and care (R01 clinical trial optional)

NIH: National Institute of Allergy and Infectious Diseases

This supports the development and testing of strategies to increase the engagement of men in HIV prevention and care within global settings and among domestic populations who have lower rates of

engagement and retention in HIV prevention and care. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Engaging men in HIV testing, prevention and care (R21 clinical trial optional)

NIH: National Institute of Allergy and Infectious Diseases

This supports the development and testing of strategies to increase the engagement of men in HIV prevention and care within global settings and among domestic populations who have lower rates of engagement and retention in HIV

prevention and care. Grants are worth up to USD 275,000 for a maximum period of two years.

Closing date: 07 Sep 21



Strategies to provide culturally tailored palliative and end-oflife care for seriously ill American Indian and Alaska Native individuals (R01 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This supports AIDS-related research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care for American Indian or Alaska Native individuals with advanced illness and their families and communities. Funding is for five years.

Closing date: 07 Sep 21

Link to *Research Professional

Strategies to provide culturally tailored palliative and end-oflife care for seriously ill American Indian and Alaska Native individuals (R21 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This supports AIDS-related research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care for American Indian and Alaska Native individuals with advanced illness and their families and communities.

Grants are worth up to USD 275,000 each over a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Processing and presentation of non-conventional MHC ligands</u> (R01 clinical trial not allowed): AIDS-related

NIH: National Institute of Allergy and Infectious Diseases

This AIDS-related funding opportunity supports the determination of antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptiic ligands and of the contribution of these unique

antigenic ligands to protective immune responses. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Processing and presentation of non-conventional MHC ligands</u> (R21 clinical trial not allowed): AIDS-related

NIH: National Institute of Allergy and Infectious Diseases



This AIDS-related funding opportunity supports the determination of antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptiic ligands and of the contribution of these unique

antigenic ligands to protective immune responses. Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Telomeres in wellness and disease – a biobehavioural</u> approach (R01 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This AIDS-related funding opportunity aims to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioural programmes of research. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Telomeres in wellness and disease – a biobehavioural</u> approach (R21 clinical trial optional): AIDS-related

NIH: National Institute of Nursing Research

This AIDS-related funding opportunity aims to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioural programmes of

research. Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

Exploratory or developmental research grant programme (parent R21 basic experimental studies with humans required): AIDS-related

NIH: National Eye Institute

This supports AIDS-related exploratory and developmental research projects in the early and conceptual stages. Awards are worth

up to USD 275,000 in direct costs for up to two years.



Closing date: 07 Sep 21

Link to *Research Professional

Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R01 clinical trial not allowed): AIDS-related

NIH: National Institute of Allergy and Infectious Diseases

This AIDS-related opportunity supports research that contributes to the overall understanding of coccidioidomycosis and other select endemic fungal diseases including histoplasmosis and blastomycosis.

The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R21 clinical trial not allowed): AIDS-related

NIH: National Institute of Allergy and Infectious Diseases

This AIDS-related funding opportunity supports research that contributes to the overall understanding of coccidioidomycosis and other select endemic fungal diseases, including histoplasmosis and blastomycosis.

Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 07 Sep 21

Link to *Research Professional

Bioengineering research grants (R01 clinical trial not allowed): AIDS-related

NIH: National Institute of Biomedical Imaging and Bioengineering

This AIDS-related call supports collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to the solution of a

biomedical problem. Grants are for up to five years.

Closing date: 07 Sep 21



Bioengineering research partnerships (U01 clinical trial not allowed): AIDS-related

NIH: National Institute of Biomedical Imaging and Bioengineering

This AIDS-related call encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The

maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Exploratory/developmental bioengineering research grants (R21 clinical trial not allowed): AIDS-related

NIH: National Cancer Institute

This AIDS-related call supports the demonstration of feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical or

clinical research, clinical care delivery or accessibility. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 07 Sep 21

Link to *Research Professional

Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R01 clinical trial not allowed): AIDS-related

NIH: National Institute on Drug Abuse

This AIDS-related funding opportunity supports the analysis of public data to increase knowledge of adolescent health and development. Grants are worth up to USD 250,000

each per year for a maximum period of five years.

Closing date: 07 Sep 21

Link to *Research Professional

Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R21 clinical trial not allowed): AIDS-related

NIH: National Institute on Drug Abuse

This AIDS-related call supports the analysis of public data to increase



knowledge of adolescent health and development. Grants are worth up to USD 275,000 each for two years.

Closing date: 07 Sep 21

Link to *Research Professional

Comparative effectiveness research in clinical neurosciences (UG3/UH3 clinical trial not allowed): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related call supports prospective observational comparative effectiveness research evaluating preventive strategies, diagnostic approaches or interventions including drugs, biologics and devices or surgical,

behavioural and rehabilitation therapies. The maximum project period is seven years.

Closing date: 07 Sep 21

Link to *Research Professional

Clinical research study planning grant programme (R34 clinical trial not allowed): AIDS-related

NIH: National Eye Institute

This AIDS-related funding opportunity supports the refinement of a study protocol and procedures and the development of a detailed manual of procedures, as well as preliminary studies to refine study procedures or document

recruitment potential. Grants are worth up to USD 150,000 each per year for up to two years.

Closing date: 07 Sep 21

Link to *Research Professional

Novel RNAs in virology and immune regulation – basic science and therapeutic discovery (R21 clinical trial not allowed): AIDS-related

NIH: National Institute of Allergy and Infectious Diseases

This AIDS-related opportunity supports basic science research in novel biologically active viral or host RNAs involved in virology, including HIV biology, and immune regulation.

Grants are worth up to USD 275,000 for two years.

Closing date: 07 Sep 21



<u>Discovery of biomarkers and biomarker signatures for</u> <u>neurological and neuromuscular disorders (R61/R33 clinical</u> <u>trial optional): AIDS-related</u>

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related funding opportunity promotes the discovery or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics

and their use in clinical practice. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 07 Sep 21

Link to *Research Professional

Mechanisms of tolerance (R21/R33 clinical trial required): AIDS-related

NIH: National Institute on Alcohol Abuse and Alcoholism

This AIDS-related funding opportunity supports research on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder.

Grants are worth up to USD 1.77 million each for up to five years.

Closing date: 07 Sep 21

Link to *Research Professional

Development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders (R01 clinical trial optional): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports research on the development of novel radioligands for positron emission tomography or single photon emission computed tomography imaging in human brain, and that incorporate pilot or

clinical feasibility evaluation in preclinical studies. The maximum project period is four years.

Closing date: 07 Sep 21



Development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of central nervous system disorders (R01 clinical trial not allowed): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related call supports the preclinical development of novel radioligands for positron emission tomography or single photon emission computed tomography imaging in rodent and nonhuman primate brain and incorporation of

pilot or clinical feasibility evaluation in preclinical studies. Grants are worth up to USD 275,000 each for up to three years.

Closing date: 07 Sep 21

Link to *Research Professional

Catalytic tool and technology development in kidney, urological and haematological diseases (R21 clinical trial not allowed): AIDS-related

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This AIDS-focused opportunity supports the development of innovative, enabling tools and technologies in the areas of kidney, urological and haematological

diseases. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 07 Sep 21

Link to *Research Professional

Research project grant (parent R01 clinical trial required): AIDS-related

NIH: National Eye Institute

This supports a discrete, specified, circumscribed AIDS-related project in areas representing the specific interests and competencies of the

investigators. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

HEAL initiative – non-addictive analgesic therapeutics development to treat pain (UG3/UH3 clinical trial not allowed): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke



This supports AIDS-related research that includes preclinical optimisation and development of safe, effective and non-addictive small molecule and biologic therapeutics to treat pain. The

maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

Notice of special interest – telehealth strategies for individuals with HIV and substance use disorders

NIH: National Institute on Drug Abuse

This supports research exploring and developing telehealth methods and strategies for diagnosis, prevention, treatment, and population analysis in individuals living with HIV and substance use disorders.

Closing date: 07 Sep 21

Link to *Research Professional

Blueprint neurotherapeutics network – biologic-based drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional): AIDS-related

NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports preclinical discovery and development of potential therapeutic biotechnology products and biologics, gene-based therapies, cell therapies and novel emerging therapies. The maximum project period is five years.

Closing date: 07 Sep 21

Link to *Research Professional

<u>Single-site investigator-initiated clinical trials (R61/R33 clinical trial required)</u>: AIDS-related

NIH: National Heart, Lung and Blood Institute

This AIDS-related call supports the development and implementation of investigator-initiated single-site clinical trials relevant to the research mission of the National Heart, Lung and Blood Institute. The

maximum project period is five years.

Closing date: 08 Sep 21



Clinical coordinating centre for multi-site investigatorinitiated clinical trials (collaborative UG3/UH3 clinical trial required): AIDS-related

NIH: National Heart, Lung and Blood Institute

This AIDS-related funding opportunity supports the development and implementation of a clinical coordinating centre for investigator-initiated multi-site clinical trials that are relevant to the research mission of the National

Heart, Lung and Blood Institute. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 08 Sep 21

Link to *Research Professional

Data coordinating centre for multi-site investigator-initiated clinical trials (collaborative U24 clinical trial required): AIDS-related

NIH: National Heart, Lung and Blood Institute

This AIDS-related call supports the implementation of a collaborating data coordinating centre for investigator-initiated multi-site clinical trials that are relevant to the research mission of the National Heart, Lung, and Blood Institute.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 08 Sep 21

Link to *Research Professional

<u>Developing digital therapeutics for substance use disorders</u> (UG3/UH3 clinical trial optional): Aids-related

NIH: National Institute on Drug Abuse

This AIDS-related funding opportunity supports research projects to accelerate the development of digital therapeutics (DTx) to treat substance use disorders (SUDs). Awards are worth

USD 500,000 in direct costs per year over three years.

Closing date: 08 Sep 21



Systems approach to understand mechanisms of heterogeneous response to influenza (R01 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports the identification of mechanisms behind heterogeneous responses in the population to influenza infection or vaccination through development and application of computational tools.

The maximum project duration is five years.

Closing date: 08 Sep 21

Link to *Research Professional

NIAID clinical trial implementation cooperative agreement (U01 clinical trial required)

NIH: National Institute of Allergy and Infectious Diseases

This supports cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Application budgets are not limited but must

reflect the actual needs of the proposed project. The maximum funding period is five years.

Closing date: 13 Sep 21

Link to *Research Professional

NIAID clinical trial planning grant (R34 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports the planning, design and preparation of the documentation necessary for implementation of investigatorinitiated clinical trials. Grants are worth up to USD 150,000 each for a maximum period of one year.

Closing date: 14 Sep 21

Link to *Research Professional

BRAIN initiative – theories, models and methods for analysis of complex data from the brain (R01 clinical trial not allowed)

NIH: National Institute of Biomedical Imaging and Bioengineering

This supports the development of new theories, computational models and analytical tools to derive understanding of brain function from complex neuroscience data. Application budgets are not limited,



but are expected to range between USD 150,000 and USD 250,000 in direct costs per year. Awards are for three years of support.

Closing date: 14 Sep 21 (Forecast)
Link to *Research Professional

Genetic architecture of mental disorders in ancestrally diverse populations (U01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports coordinated efforts to accelerate gene discovery for psychiatric disorders in cohorts of non-European ancestry to boost efforts to fine-map genetic risk loci across the allelic spectrum and

advance global mental health equity. The maximum project period is five years.

Closing date: 15 Sep 21

Link to *Research Professional

Genetic architecture of mental disorders in ancestrally diverse populations (collaborative U01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports coordinated efforts on multiple sites to accelerate gene discovery for psychiatric disorders in cohorts of non-European ancestry to boost efforts to fine-map genetic risk loci across the allelic spectrum and advance global mental health equity. Grants are worth up to USD 500,000 each for five years.

Closing date: 15 Sep 21

Link to *Research Professional

Blueprint for neuroscience research – tools and technologies to explore nervous system biomolecular condensates (R21 clinical trial not allowed)

NIH: National Institute on Drug Abuse

This supports a collaborative framework for neuroscience related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. The total budget is

worth USD 1.2 million to fund projects worth up to USD 275,000 each over two years.

Closing date: 15 Sep 21



High-throughput discovery and validation of novel signal transducers or small molecules that modulate opioid or other substance use disorder relevant pathways (R01 – clinical trials not allowed)

NIH: National Institute on Drug Abuse

This supports high-throughput screening approaches to identify novel receptors, signal transducers, or small molecules that modulate Substance Use Disorder-relevant signal transduction pathways.

Grants are worth up to USD 400,000 each per year over a maximum period of five years.

Closing date: 15 Sep 21

Link to *Research Professional

Mechanism-focused research to promote adherence to healthful behaviours to prevent mild cognitive impairment and Alzheimer's disease and related dementias (R01 clinical trial optional)

NIH: National Institute on Aging

This supports ancillary studies that address psychological and interpersonal mechanisms driving adherence to behaviour or lifestyle change relevant to the prevention of cognitive decline, mild cognitive impairment and Alzheimer's disease

and Alzheimer's disease-related dementias. The maximum project period is five years.

Closing date: 15 Sep 21

Link to *Research Professional

Mechanism-focused research to promote adherence to healthful behaviours to prevent mild cognitive impairment and Alzheimer's disease and related dementias (R61/R33 clinical trial required)

NIH: National Institute on Aging

This supports research focused on psychological and interpersonal mechanisms driving adherence to behaviours or lifestyle changes relevant to prevention of cognitive decline, mild cognitive impairment, and Alzheimer's disease and

Alzheimer's disease-related dementias. Grants are worth up to USD 500,000 each per year for a maximum of five years.

Closing date: 15 Sep 21



<u>Clinical characterisation of cancer therapy-induced adverse</u> <u>sequelae and mechanism-based interventional strategies (R01</u> clinical trial optional)

NIH: National Cancer Institute

This supports collaborative research projects that address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. The maximum project period is five years.

Closing date: 20 Sep 21

Link to *Research Professional

Biomedical knowledgebase (U24 clinical trials not allowed)

NIH: National Institute of General Medical Sciences

This supports the extraction, accumulation, organisation, annotation and linking of growing bodies of information related to core

datasets. The maximum project period is five years.

Closing date: 24 Sep 21

Link to *Research Professional

Biomedical data repository (U24 – clinical trials not allowed)

NIH: National Institute of General Medical Sciences

This supports biomedical data repositories whose primary function is to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. The

maximum project period is five years.

Closing date: 24 Sep 21

Link to *Research Professional

Novel synthetic nucleic acid technology development (R01 clinical trial not allowed)

NIH: National Human Genome Research Institute

This supports the development of novel technologies that will enable substantive improvement in synthetic nucleic acids. Grants are worth up to USD 700,000 each for year for up to three years.

Closing date: 01 Oct 21



Novel synthetic nucleic acid technology development (R21 clinical trial not allowed)

NIH: National Human Genome Research Institute

This supports the development of novel technologies that will enable substantive improvement in synthetic nucleic acids. Grants are worth up to USD 400,000 each for up to three years.

Closing date: 01 Oct 21

Link to *Research Professional

<u>Limited competition – modular budget research project grant</u> <u>for NIH nurse scientist scholars (R01 clinical trial optional)</u>

NIH: National Institute of Nursing Research

This supports research projects conducted by NIH-supported nurse scientists in order to help accelerate their transition to independent investigator status. Application budgets are worth up to USD

250,000 in direct costs per year for up to five years.

Closing date: 04 Oct 21

Link to *Research Professional

Identification of positive valence system related targets for novel suicide prevention approaches (R01 clinical trial optional)

NIH: National Institute of Mental Health

This supports research projects that will advance translational research to better understand risk and resilience for suicide in the context of the institute's research domain criteria framework, specifically the positive valence systems domain, and lead to novel interventions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 21

Link to *Research Professional

Ethical issues in translational science research (R01 clinical trial optional)

NIH: National Center for Advancing Translational Sciences

This supports research on ethical issues in translational science

research. Grants are worth up to USD 300,000 each in direct costs per



year for a maximum period of four years.

Closing date: 06 Oct 21

Link to *Research Professional

BRAIN initiative – development and validation of novel tools to probe cell-specific and circuit-specific processes in the brain (R01 clinical trial not allowed)

NIH: National Institute of Mental Health

This supports the development and validation of novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie

brain function. Funding is for up to three years.

Closing date: 08 Oct 21

Link to *Research Professional

Secondary analyses of existing datasets of tobacco use and health (R21 clinical trial not allowed)

NIH: National Cancer Institute

This supports the innovative analysis of existing and publicly available datasets that may inform tobacco regulatory actions in the US. Awards are worth up to USD

275,000 each for a maximum period of two years.

Closing date: 08 Oct 21

Link to *Research Professional

Maximising the scientific value of existing biospecimen collections (R21 clinical trial not allowed)

NIH: National Cancer Institute

This supports exploratory research relevant to the mission of the Food and Drug Administration's Center for Tobacco Products using existing biospecimens currently stored in repositories in the US. Grants are worth up to USD 275,000 each over a maximum of two years.

Closing date: 08 Oct 21

Link to *Research Professional

<u>COMING SOON: Secondary analyses of existing datasets of tobacco use and health (R21 clinical trial not allowed)</u>

NIH: Office of the Director



This opportunity supports innovative analysis of existing US cross-sectional and longitudinal data, to investigate novel scientific ideas or to generate new models, systems, tools, methods or technologies that have the potential

for significant impact on biomedical or biobehavioural research in tobacco. Grants are worth up to USD 275,000 for up to two years.

Closing date: 08 Oct 21 (Forecast)
Link to *Research Professional

Extracellular RNA carrier subclasses in processes relevant to substance use disorders or HIV infection (R01 clinical trial not allowed)

NIH: National Institute on Drug Abuse

This supports research investigating the roles of extracellular RNA carrier subclasses in biological processes relevant to substance use disorders or HIV infection, latency or pathogenesis in the central nervous system. The maximum project period is five years.

Closing date: 13 Oct 21

Link to *Research Professional

Extracellular RNA carrier subclasses in processes relevant to substance use disorders or HIV infection (R21 clinical trial not allowed)

NIH: National Institute on Drug Abuse

This supports research that investigates the roles of extracellular ribonucleid acid carrier subclasses in biological processes relevant to substance use disorders or HIV infection. Awards are worth up to

USD 275,000 each for up to two years.

Closing date: 13 Oct 21

Link to *Research Professional

Exploratory clinical neuroscience research on substance use disorders (R61/R33 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports exploratory and developmental clinical research that focuses on understanding the neurobiological mechanisms underlying substance use disorders, including fundamental brain function relevant to substance use. The maximum funding period is five years.



Closing date: 13 Oct 21

Link to *Research Professional

<u>Administrative supplements for research on dietary</u> <u>supplements (admin supp clinical trial not allowed)</u>

NIH: National Institutes of Health

This supports research in which the supplemental funding investigates the role of dietary supplements or their ingredients in health maintenance and disease prevention. Grants are worth up to

USD 100,000 in direct costs for one year.

Closing date: 15 Oct 21

Link to *Research Professional

BRAIN initiative – integration and analysis of BRAIN initiative data (R01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This aims to develop informatics tools for analysing, visualising and integrating data related to the BRAIN initiative or to enhance understanding of the brain.

Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is three years.

Closing date: 15 Oct 21

Link to *Research Professional

<u>Understanding and reducing cardiovascular disease in type 1</u> <u>diabetes mellitus (R01 – clinical trial optional)</u>

NIH: National Heart, Lung and Blood Institute

This supports research that enhances the understanding of the pathophysiology, risk factors, early detection and treatment of cardiovascular disease among individuals with type 1 diabetes mellitus. Awards are worth up to USD 500,000 per year for a maximum of five years.

Closing date: 15 Oct 21



Identification of positive valence system related targets for novel suicide prevention approaches (R21 clinical trial optional)

NIH: National Institute of Mental Health

This supports research projects that will advance translational research to better understand risk and resilience for suicide in the context of the institute's research domain criteria framework, specifically the positive valence systems domain,

and lead to novel interventions. Awards are worth up to USD 275,000 each over two years.

Closing date: 16 Oct 21

Link to *Research Professional

BRAIN initiative – pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports the evaluation of molecular or genetic technologies and the creation of pilot production and distribution resources for cell type-specific access and manipulation reagents for several

vertebrate species. The maximum project period is three years.

Closing date: 19 Oct 21

Link to *Research Professional

Development of new technologies and bioengineering solutions for the advancement of cell replacement therapies for type 1 diabetes (R01 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports research addressing barriers that limit progress toward effective cell replacement therapies for type 1 diabetes. Application budgets are limited to USD 500,000 direct costs per year for a maximum duration of five years.

Closing date: 20 Oct 21



Advancing technologies to improve delivery of pharmacological, gene editing and other cargoes for HIV and substance use disorders mechanistic or therapeutic research (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports the development of technologies to improve the delivery of pharmacological, gene editing or other cargoes for HIV and substance use disorders mechanistic research. The maximum project period is five years.

Closing date: 25 Oct 21

Link to *Research Professional

Secondary analysis of existing datasets in heart, lung and blood diseases and sleep disorders (R21 clinical trial not allowed)

NIH: National Heart, Lung and Blood Institute

This enables the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods or technologies that have the potential for significant impact on biomedical

or biobehavioural research in areas relevant to the institute's mission. Grants are worth up to USD 150,000 each for a two year period.

Closing date: 28 Oct 21

Link to *Research Professional

BRAIN initiative – new concepts and early-stage research for large-scale recording and modulation in the nervous system (R21 clinical trial not allowed)

NIH: National Eye Institute

This seeks applications for unique and innovative recording or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualisation. Application

budgets may not exceed USD 400,000 in direct costs over a maximum three-year funding period.

Closing date: 29 Oct 21